ASX Quarterlies: Nuheara rockets 33pc, Dicker continues to grow, while these biotechs are all cashed up
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.